Triazoles (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514075000 - Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI

514079000 - Nitrogen containing hetero ring

514091000 - Hetero ring is five-membered

514092000 - Two or more hetero atoms in the five-membered ring

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application number	Description	Number of patent applications / Date published
514093000	Triazoles (including hydrogenated)	6
20100093670	Compounds for the treatment of angiogenesis - The invention relates to isoxazole, isothiazole, and triazole compounds that are useful for treating or inhibiting angiogenesis.	04-15-2010
20120010173	Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations - The invention relates to a compound of formula (I) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R	01-12-2012
20130072461	TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.	03-21-2013
20130338112	COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to compounds of structural formula (I):	12-19-2013
20150320866	PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER - The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration. Also described are methods of treatment of various disorders, including chemotherapy-induced nausea and vomiting (CINV). The disclosed compositions and methods provide for less frequent dosing of the therapeutic agents, thereby increasing subject comfort and compliance.	11-12-2015
20170232107	PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER	08-17-2017